4F-MPH 30 MG Peletler (4-Florometilfenidat)
4F-MPH 30 MG Peletler (4-Florometilfenidat) Fiyat aralığı: €18.95 ile €549.95 arası
Ürünlere geri dön
1cP-MiPLA 200 MCG Blotterleri
1cP-MiPLA 200 MCG Blotterleri Fiyat aralığı: €6.50 ile €399.95 arası

IDRA-21 10 MG Peletler

IDRA-21 Pellets properties

Eş anlamlısı : 7-kloro-3-metil-3,4-dihidro-2H-1,2,4-benzotiadiazin 1,1-dioksit
CAS Sayı : 22503-72-6
Formül : C8H9ClN2O2S
Mol kütlesi : 232,6 g/mol
Saflık : >97%

Fiyat aralığı: €13.50 ile €398.58 arası

* Bu sayfadaki bilgiler özet niteliğindedir ve bu ilaçla ilgili mevcut tüm bilgileri kapsaması amaçlanmamıştır. Olası tüm kullanımları, talimatları, önlemleri, ilaç etkileşimlerini veya yan etkileri kapsamaz ve sağlık uzmanınızın uzmanlığının ve yargısının yerine geçmez.

IDRA-21 10 MG Pellets – Scientific Description & User Manual

Ürün Açıklaması

IDRA-21 (10 mg pellets)  is a potential  AMPA receptor potentiator  belonging to the class of  nootropic and neuroprotective research chemicals . It works by enhancing glutamate-induced signaling in the brain, which may lead to improved cognitive function, neuroplasticity, and potentially neurorecovery.

Bu peletler  highly pure (≥98%) , standardized dosed and intended solely for  scientific research and preclinical studies .


Uses & Applications

IDRA-21 is being studied for its possible effects on:

  1. Cognitive Enhancement  – ​​May increase alertness, learning ability, and memory consolidation.

  2. Neuroprotection  – Potential protective effect in neurodegenerative diseases (e.g. Alzheimer’s, stroke).

  3. Neurological Recovery  – May Promote Synaptic Plasticity After Brain Injury.

  4. Scientific Research  – Study of AMPA receptor modulation and glutamate signaling.

⚠ Not approved for human or veterinary use – For in vitro and controlled preclinical studies only.


Dosage & Safety Guidelines

  • Investigational dosage (in vitro/preclinical):  5–20 mg/kg  (depending on model).

  • Pellet Solution:  Can be dissolved in  distilled water or DMSO  for experiments.

  • Administration:  Orally (animal models) or directly in cell cultures.

  • Frequency:  Single dose for acute effect; long-term studies require careful monitoring.

🚨 NB:

  • No human application  – No safety data for human use.

  • High doses may cause neuroexcitotoxicity.

  • Avoid combination with other glutamate modulators.


Disadvantages & Risks

  • Overstimulation of neurons  (risk of excitotoxicity in case of overdose).

  • Possible anxiety or agitation  in susceptible models.

  • Limited long-term data  on tolerance and adverse effects.

  • Not suitable for chronic use  without extensive toxicity studies.


Sıkça Sorulan Sorular (SSS)

1. Is IDRA-21 legal in the Netherlands?

Yes, but only for  bilimsel araştırma . It doesn’t fall under the Opium Act, but it’s also not approved as a medicine.

2. How exactly does IDRA-21 work?

It  enhances the AMPA receptor response , making glutamate signaling longer and more intense. This can lead to improved synaptic communication.

3. Can IDRA-21 be compared to other nootropics?

It has a unique mechanism of action, but  similar targets as racetams or ampakines  (e.g. Sunifiram).

4. Are there any known interactions?

  • NMDA antagonists  (e.g. memantine) – Potentially adverse effects.

  • GABAergic agents  (e.g., benzodiazepines) – May reduce anxiolytic effects.


Laboratuvar Raporu ve Kalite Kontrolü

  • HPLC analysis:  ≥98% purity .

  • No detectable heavy metals or solvent residues .

  • Homogeneous pellet formulation  for consistent dosing.

  • Batch certification  available for research institutions.


Recommended Research Scenarios

  1. Cognitive studies  – Effects on memory and learning in animal models.

  2. Neuroprotective research  – Potential role in ischemic injury (stroke models).

  3. Elektrofizyoloji  – AMPA receptor response measurements in neuronal cultures.

🔬 For controlled laboratory use only – No recreational use!